MicroRNA-mediated drug resistance in ovarian cancer
Mihanfar A, Fattahi A, Nejabati HR (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Journal
Book Volume: 234
Pages Range: 3180-3191
Journal Issue: 4
DOI: 10.1002/jcp.26060
Abstract
The development of intrinsic or acquired resistance to chemotherapeutic agents used in the treatment of various human cancers is a major obstacle for the successful abolishment of cancer. The accumulated efforts in the understanding the exact mechanisms of development of multidrug resistance (MDR) have led to the introduction of several unique and common mechanisms. Recent studies demonstrate the regulatory role of small noncoding RNA or miRNA in the several parts of cancer biology. Practically all aspects of cell physiology under normal and disease conditions are reported to be controlled by miRNAs. In this review, we discuss how the miRNA profile is changed upon MDR development and the pivotal regulatory role played by miRNAs in overcoming resistance to chemotherapeutic agents. It is hoped that further studies will support the use of these differentially expressed miRNAs as prognostic and predictive markers, as well as novel therapeutic targets to overcome resistance in ovarian cancer.
Additional Organisation(s)
Involved external institutions
Iran, Islamic Republic of (IR)How to cite
APA:
Mihanfar, A., Fattahi, A., & Nejabati, H.R. (2019). MicroRNA-mediated drug resistance in ovarian cancer. Journal of Cellular Physiology, 234(4), 3180-3191. https://dx.doi.org/10.1002/jcp.26060
MLA:
Mihanfar, Aynaz, Amir Fattahi, and Hamid Reza Nejabati. "MicroRNA-mediated drug resistance in ovarian cancer." Journal of Cellular Physiology 234.4 (2019): 3180-3191.
BibTeX: Download